United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,168

Sector

Biotechnology & Medical Research

Calendar

18/02/2025 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
06/12/24	369.67 $	-1.26%	199,272
05/12/24	374.37 $	-0.01%	241,661
04/12/24	374.40 $	+1.52%	151,255
03/12/24	368.79 $	-0.36%	235,135
02/12/24	370.12 $	-0.10%	315,271

Delayed Quote Nasdaq, December 06, 2024 at 09:00 pm

More quotes

Income Statement and Estimates

income-statement-evolution-chart UNITED-THERAPEUTICS-CORPO

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

369.67USD

Average target price

382.22USD

Spread / Average Target

+3.40%

Consensus

Profit revisions

estimates-change-chart UNITED-THERAPEUTICS-CORPO

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart UNITED-THERAPEUTICS-CORPO

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 06/12/2024 GMT			5-day change	1st Jan Change
369.67 ^USD	-1.26%		-0.22%	+68.12%

11-22	United Therapeutics Insider Sold Shares Worth $2,828,672, According to a Recent SEC Filing	MT
11-12	United Therapeutics Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 02:45 PM

Capitalization	16.5B 15.62B 14.48B 12.95B 23.33B 1,398B 25.83B 180B 66.6B 574B 62B 60.62B 2,474B	P/E ratio 2024 *	15.1x	P/E ratio 2025 *	13.3x
Enterprise value	14.34B 13.57B 12.58B 11.25B 20.27B 1,214B 22.44B 157B 57.86B 499B 53.86B 52.67B 2,150B	EV / Sales 2024 *	4.98x	EV / Sales 2025 *	4.15x
Free-Float	-	Yield 2024 *	-	Yield 2025 *	-

United Therapeutics Insider Sold Shares Worth $2,828,672, According to a Recent SEC Filing	11-22	MT
United Therapeutics Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 02:45 PM	11-12
BETA Technologies, Inc. announced that it has received $318.437454 million in funding from Qatar Investment Authority, Fidelity Management & Research Company LLC, TPG Capital, L.P., United Therapeutics Corporation and other investors	10-30	CI
United Therapeutics Seeks M&A	10-30	CI
United Therapeutics Corporation, Q3 2024 Earnings Call, Oct 30, 2024	10-30
United Therapeutics' Q3 Earnings, Revenue Rise	10-30	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Posts Q3 Revenue $748.9M	10-30	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	10-30	CI
United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	10-30	CI
BETA Technologies, Inc. announced a financing transaction	10-23	CI
United Therapeutics Insider Sold Shares Worth $2,855,916, According to a Recent SEC Filing	10-22	MT
Sector Update: Health Care Stocks Retreat Late Afternoon	10-07	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	10-07	MT

Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating	08-28	MT
UBS Adjusts Price Target on United Therapeutics to $365 From $370, Maintains Buy Rating	08-01	MT
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target	08-01	MT
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating	07-25	MT
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing	07-17	MT

United Therapeutics Corporation Share Price

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Valuation: United Therapeutics Corporation

Chart: United Therapeutics Corporation

Latest news: United Therapeutics Corporation

Last Transcript: United Therapeutics Corporation

Analysts' recommendations: United Therapeutics Corporation

Press Releases: United Therapeutics Corporation

News in other languages: United Therapeutics Corporation

Quotes and Performance

Course Extremes

Managers and Directors: United Therapeutics Corporation

ETFs: United Therapeutics Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference	11-05	BU
United Therapeutics : Third Quarter 2024 Factsheet	10-30	PU
United Therapeutics : Reports Third Quarter 2024 Financial Results Form 8 K	10-30	PU
United Therapeutics : Third Quarter 2024 Financial Results Presentation	10-30	PU
United Therapeutics: Q3 Earnings Snapshot	10-30	AQ

Pfizer acquiert le laboratoire Arena Pharmaceuticals	13/12/21
MÄRKTE USA/Börse hakt schwache Daten ab - Technologiewerte gesucht	18/10/21
MÄRKTE USA/Erholt von Anfangsverlusten - Technologiewerte vorne	18/10/21
Novartis/Sandoz obtient une extension d'indication pour Treprostinil aux USA	24/05/21
Novartis-Tochter Sandoz erhält Indikationserweiterung für PAH-Medikament in USA	24/05/21

1 day	-1.26%
1 week	-0.22%
Current month	-0.22%
1 month	-9.84%
3 months	+6.96%
6 months	+34.43%
Current year	+68.12%

Director	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	69	25/06/1996
Michael Benkowitz PSD	President	52	25/06/2016
James Edgemond DFI	Director of Finance/CFO	56	12/03/2015

Manager	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	76	31/12/2001
Martine Rothblatt CHM	Chairman	69	25/06/1996
Louis Sullivan BRD	Director/Board Member	90	31/12/2001

Name	Weight	AuM	1st Jan change	Investor Rating
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.06%	1 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	2.87%	2 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
UNITED THERAPEUTICS CORPORATION	-1.26%	-0.22%	+52.98%	+90.61%	16.5B
LONZA GROUP AG	+0.42%	-0.80%	+58.63%	-29.66%	43B
IQVIA HOLDINGS INC.	+1.35%	+0.89%	-5.88%	-25.56%	36.78B
CELLTRION, INC.	-0.50%	-3.69%	+7.39%	-7.93%	26.11B
ICON PUBLIC LIMITED COMPANY	+3.81%	+3.43%	-20.18%	-21.89%	17.95B
MODERNA, INC.	+3.49%	+3.20%	-44.67%	-84.32%	17.1B
BIO-TECHNE CORPORATION	+0.84%	-1.13%	+9.08%	-38.08%	11.84B
MEDPACE HOLDINGS, INC.	+2.40%	+2.91%	+23.78%	+64.07%	10.87B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.14%	-3.64%	-6.19%	-47.59%	9.81B
QIAGEN N.V.	-0.02%	-0.02%	+0.83%	-23.09%	9.65B
Average	+1.07%	+0.22%	+7.58%	-12.34%	19.96B
Weighted average by Cap.	+1.00%	+0.15%	+12.82%	-16.06%

	2024 *	2025 *
Net sales	2.88B 2.73B 2.53B 2.26B 4.07B 244B 4.51B 31.46B 11.63B 100B 10.83B 10.59B 432B	3.18B 3.01B 2.79B 2.5B 4.5B 269B 4.98B 34.72B 12.84B 111B 11.95B 11.68B 477B
Net income	1.19B 1.13B 1.05B 936M 1.69B 101B 1.87B 13.03B 4.82B 41.53B 4.48B 4.38B 179B	1.29B 1.22B 1.13B 1.01B 1.82B 109B 2.02B 14.06B 5.2B 44.83B 4.84B 4.73B 193B
Net Debt	-2.16B -2.05B -1.9B -1.7B -3.06B -183B -3.39B -23.63B -8.74B -75.32B -8.13B -7.95B -325B	-3.29B -3.12B -2.89B -2.58B -4.66B -279B -5.15B -35.94B -13.29B -115B -12.37B -12.09B -494B